Business Segments · Net loss
Reportable Segment — Net loss
Insmed Reportable Segment — Net loss increased by 55.8% to -$163.56M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ3 2024
Last reportedQ1 2026
Rolls up toNet Income
How to read this metric
A narrowing loss indicates improved operational efficiency or revenue growth, while a widening loss suggests rising costs or declining market performance.
Detailed definition
This metric represents the bottom-line financial result for the specific business segment after deducting all operating...
Peer comparison
Common in biopharma segments during the commercialization or clinical development phase where R&D costs often exceed product revenue.
Metric ID:
insm_segment_reportable_segment_net_lossHistorical Data
4 periods
| Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|
| Value | -$220.52M | -$256.58M | -$370.02M | -$163.56M |
| QoQ Change | — | -16.4% | -44.2% | +55.8% |
| YoY Change | — | — | -67.8% | +36.3% |
Range-$370.02M – -$163.56M
Avg YoY Growth-15.8%
Median YoY Growth-15.8%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Insmed's reportable segment — net loss?
- Insmed (INSM) reported reportable segment — net loss of -$163.56M in Q1 2026.
- What does reportable segment — net loss mean?
- The total financial loss incurred by this specific business segment after accounting for all related costs and revenues.